High Intensity Focused Ultrasound Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Unilateral HIFU: More Cons Than Pros(tate)?Unilateral HIFU: More Cons Than Pros(tate)?
A small study of high-intensity focused ultrasound in localized prostate cancer fails to make the case for this treatment option, says Dr Gerald Chodak. Medscape Urology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

HIFU in Prostate Cancer: Are Patients 'Guinea Pigs'?HIFU in Prostate Cancer: Are Patients 'Guinea Pigs'?
The FDA rejected high-intensity ultrasound (HIFU) for treating prostate cancer and then approved a device as safe for 'prostate ablation.' Is that a mixed message? Medscape Urology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 3, 2016 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news

ERP Therapy, Where Are You?
I recently received an email from a woman in her thirties who has had obsessive-compulsive disorder since she was a child. She came across one of my articles and was interested in learning more about exposure and response prevention (ERP) therapy, as she had never heard of it. She had been to all kinds of health care providers over the years, yet she had never heard of ERP. Unfortunately, emails such as hers are not uncommon, but they sure are frustrating. She’s had OCD for twenty plus years and never heard of ERP? This realization jolts me out of my little corner of the world (or blogosphere) where everyone knows about ...
Source: Psych Central - February 15, 2016 Category: Psychiatry Authors: Janet Singer Tags: Cognitive-Behavioral Disorders General Obsessive-Compulsive Disorder Personal Stories Psychiatry Psychology Psychotherapy Treatment Avoidance Cognitive Behavioral Therapy Compulsions Erp exposure and response prevention Exposur Source Type: news

Experimental ultrasound treatment zaps cancer pain
High-intensity focused ultrasound blasts cells that trigger pain; "When the pain is less, or the pain is gone, you're back to being normal" (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 29, 2016 Category: Consumer Health News Source Type: news

12 Amazing Things We Learned About The Human Body In 2015
The human body is a source of mystery. But every year, scientists get just a little better at understanding its secrets. Of course, 2015 has been no different. In the past year, researchers have created better access to proven therapies, developed futuristic new technologies that may change the way we approach disease and even enacted more complete disease screening processes to keep us healthy. Read on to learn more. Here’s to more scientific discoveries in 2016! @media (max-width: 969px) { #desktop { display: none; } } @media (min-width: 970px) { #mobile { display: none; } } #g-body...
Source: Science - The Huffington Post - December 22, 2015 Category: Science Source Type: news

Celsion wins Chinese approval for ThermoDox study
Oncology drug developer Celsion has won clinical trial approval from the China...Read more on AuntMinnie.comRelated Reading: FDA approves Philips, Celsion HIFU study Celsion, Philips resubmit MR-HIFU study Celsion, Focused Ultrasound support HIFU trials Philips, Celsion research program moves forward Philips inks research agreement with Celsion (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 16, 2015 Category: Radiology Source Type: news

EDAP Receives Russian Regulatory Approval for Focal One(R) HIFU Device
LYON, France, Dec. 11, 2015 -- (Healthcare Sales & Marketing Network) -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced that Russia's Federal Service for Surveillance in Healthcare (Roszdravnadzor) has approved Focal One f... Devices, Oncology, Urology, RegulatoryEDAP TMS, Ablatherm, HIFU, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2015 Category: Pharmaceuticals Source Type: news

Edap slips shareholders lawsuit
Edap (NSDQ:EDAP) said yesterday that the appeal deadline lapsed for a shareholders lawsuit filed after an FDA advisory panel recommended against approval for its its Ablatherm device for treating prostate cancer. EDAP shares plunged last year after the FDA’s Gastroenterology & Urology Devices panel voted that the device did not appear to be effective or safe. Ablatherm, which won 510(k) clearance from the federal safety watchdog earlier this week, uses highhigh-intensity focused ultrasound to ablate prostate tissue. Shareholders sued in August 2014, accusing Edap of misleading investors by exaggerating Abla...
Source: Mass Device - November 12, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Legal News Radiosurgery Urology EDAP TMS SA Source Type: news

Prostate HIFU available for 1st time in U.S.
HIFU Prostate Services, a provider of minimally invasive prostate cancer treatment...Read more on AuntMinnie.comRelated Reading: SonaCare lands FDA nod for HIFU system (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 9, 2015 Category: Radiology Source Type: news

FDA clears Edap’s Ablatherm prostate device
Edap (NSDQ:EDAP) said today that it won 510(k) clearance from the FDA for its Ablatherm, less than a month after a similar device from rival SonaCare won a nod from the federal safety watchdog. The Ablatherm device, like SonaCare’s Sonablate 450, is designed to ablate prostate tissue using high-intensity focused ultrasound. After a years-long dance with the FDA that saw it move from a pre-market approval application to a de novo bid, Edap applied for 510(k) clearance after the agency cleared the Sonablate 450 in October. Today the Lyon, France-based company said it expects to begin marketing the device in the U...
Source: Mass Device - November 9, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Radiosurgery Regulatory/Compliance Urology EDAP TMS SA SonaCare Medical Source Type: news

Study Oversells HIFU Benefits, Especially in Low-Risk PCaStudy Oversells HIFU Benefits, Especially in Low-Risk PCa
Dr Gerald Chodak disputes the conclusions of a study comparing HIFU therapy with brachytherapy for patients with low or intermediate-risk prostate cancer. Medscape Urology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 23, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA Approves First HIFU Device for Prostate Tissue AblationFDA Approves First HIFU Device for Prostate Tissue Ablation
After being nixed by their advisory committee last year, Sonablate 450, for use in prostate tissue ablation, has now received the green light from the FDA. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Insightec files PMA for Exablate Neuro
Insightec said today it submitted a premarket approval application to the FDA for its Exablate Neuro device seeking an indication to treat essential tremors. The Exablate Neuro uses high intensity focused ultrasound to thermally ablate targeted tissue and uses continuous magnetic resonance imaging to visualize anatomy to plan and monitor treatments and outcomes. The MR-guided focused ultrasound procedure can be performed non-invasively through an intact skull to relieve tremors in patients with essential tremors, the Israel-based company said. “This is another major achievement, our third clinical indication submitt...
Source: Mass Device - October 22, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Pre-Market Approval (PMA) Regulatory/Compliance Ultrasound InSightec Ltd Source Type: news

FDA clears SonaCare HIFU prostate device, prompts Edap to yank de novo, go for 510k
SonaCare said it won FDA pre market approval for its high intensity focused ultrasound device designed to treat prostate cancer, causing competitor EDAP (NSDQ:EDAP) to yank the de novo application for its Ablatherm HIFU. SonaCare said its Sonablate 450 will be available in the U.S. this October. “The FDA regulatory authorization to market Sonablate in the U.S. is a milestone for non-invasive prostate care and a tremendous gain for men’s health. Men all over the world, in the more than 49 countries where it has already been authorized for use, have had access to this technology for prostate ablation. There are nume...
Source: Mass Device - October 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology Pre-Market Approval (PMA) Regulatory/Compliance EDAP TMS SA SonaCare Medical Source Type: news

Focused ultrasound trial for depression gets underway
A team from Yonsei University College of Medicine in Seoul, South Korea, has...Read more on AuntMinnie.comRelated Reading: BCBS updates coverage for InSightec's MRgFUS DC docs use MR-HIFU to treat bone tumor Philips, Infraredx announce resale agreement Philips sells MR-HIFU unit in Jordan Celsion, Focused Ultrasound support HIFU trials (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 29, 2015 Category: Radiology Source Type: news